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Abstract: Advanced glycation end products (AGEs) have been implicated in the pathophysiology
of type 2 diabetes and cardiovascular disease. We aimed to determine the associations of
urinary carboxymethyl-lysine (CML) and methylglyoxal-hydroimidazolone (MG-H1) levels with
cardiometabolic parameters in metabolically healthy obese women. Anthropometric, glycemic,
cardiovascular, and urinary AGE parameters were measured in 58 metabolically healthy obese
women (age: 39.98 ± 8.72 years; body mass index (BMI): 32.29 ± 4.05 kg/m2). Urinary CML levels were
positively associated with BMI (r = 0.29, p = 0.02). After adjustment for age and BMI, there was a trend
for positive associations between urinary CML levels and fasting (p = 0.06) and 2 h insulin (p = 0.05)
levels, and insulin resistance measured by homeostatic model assessment (HOMA-IR) (p = 0.06).
Urinary MG-H1 levels were positively associated with systolic and diastolic blood pressure, pulse
pressure, mean arterial pressure, and total and low-density lipoprotein cholesterol after adjustment for
age, BMI, and HOMA-IR (all p < 0.05). There were no associations between urinary CML levels and
cardiovascular parameters, and between urinary MG-H1 levels and glycemic measurements. Our data
support a role of urinary AGEs in the pathophysiology of insulin resistance and cardiovascular
disease; however, future studies are highly warranted.
Keywords: advanced glycation end products; carboxymethyl-lysine; methylglyoxal-derived
hydroimidazolone; insulin resistance; type 2 diabetes; cardiovascular disease
1. Introduction
Advanced glycation end products (AGEs) are formed when proteins or lipids become
non-enzymatically glycated after exposure to sugars [1]. AGEs are formed endogenously at lower
rates under normal physiological conditions [2], but their formation is increased in patients with
impaired glucose metabolism [3]. Accumulation of AGEs has been implicated in the development
of several chronic diseases, including type 2 diabetes (T2DM), cardiovascular disease (CVD), and
neurodegenerative disease (Alzheimer’s and Parkinson’s diseases) through altering the structure and
functions of proteins or by increasing inflammation and oxidative stress [4].
Carboxymethyl-lysine (CML) and methylglyoxal-derived hydroimidazolone (MG-H1) are the
most commonly measured and well-described non-fluorescent AGEs in blood, urine, and feces [4].
CML and MG-H1, which are derived from lysine and arginine, are important to estimate overall AGE
exposure [5]. The measurement of protein bound AGEs requires complicated sample preparation or
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the development of stable antibodies [6]. Urinary AGEs, which is easily accessible in a non-invasive
manner and can be detected using relatively easily and inexpensive methods, have been suggested to
reflect circulating AGEs in healthy individuals with normal renal function [6,7]. Published studies,
however, have shown contradictory findings with regards to the relationships between urinary AGE
levels and cardiometabolic risk factors. One study reported positive associations between urinary
AGE levels and anthropometric and metabolic parameters in healthy individuals and patients with
metabolic syndrome [6], while other studies in individuals with and without T2DM did not [7,8].
However, these studies reported either total urinary AGEs or CML levels [6–8], and no studies have
thus far investigated the associations between urinary MG-H1 levels and cardiometabolic parameters.
The hypothesis of the present study was to determine whether urinary CML and MG-H1 levels were
associated with cardiometabolic parameters in metabolically healthy obese women.
2. Materials and Methods
2.1. Study Design and Population
This was a cross-sectional analysis of baseline data from a randomized controlled trial that was
conducted in healthy overweight and obese Caucasian women at the Department of Nutrition, Exercise,
and Sports, University of Copenhagen, Denmark. As previously reported [5], women aged 20–50 years
with a body mass index (BMI) of 25–40 kg/m2 and a waist circumference of >88 cm were included in
the study. Participants were excluded from the study if they were current smokers, pregnant/lactating,
vegetarian/vegan, physically active for more than 8 h per week, or allergic to para-aminobenzoic acid.
Women who had weight change of >3 kg in the previous two months, known medical or postmenstrual
conditions, gastric bypass surgery, or those who had donated blood in the last three months or used
supplements/medications were also excluded. The study population was well characterized with
regard to anthropometric, metabolic, cardiovascular, and AGEs measurements. Participants were asked
to restrain from rigorous physical activity and alcohol consumption for 48 h before all measurements.
This study was carried out in accordance with the recommendations of local ethics guidelines, Danish
Research Ethics Committee. The protocol was approved by the Danish Research Ethics Committee
(#H-4-2011-077). All subjects gave written informed consent in accordance with the Declaration
of Helsinki.
2.2. Anthropometric Measurements
Weight, height, and waist and hip circumferences were measured using standard equipment and
methods. BMI was calculated as weight (kg)/height (m) square, while waist-to-hip ratio (WHR) was
computed as waist (cm)/hip (cm).
2.3. Cardiovascular Measurements
Blood pressure was measured using an automated oscillometric measurement and was assessed
in a sitting position after 30 min of rest. The mean of three measurements, separated by 5 min, was
recorded. Pulse pressure was calculated by subtracting diastolic blood pressure from systolic blood
pressure. Mean arterial pressure was computed using ((diastolic blood pressure × 2) + systolic blood
pressure)/3. Plasma lipid levels including total cholesterol, triglycerides, low-density lipoprotein
(LDL), and high-density lipoprotein (HDL) cholesterol were measured using an enzymatic colorimetric
method (Horiba, Montpellier, France).
2.4. Metabolic Measurements
A 75 g oral glucose tolerance test (OGTT) was performed after a 12 h overnight fast and
blood samples were drawn at 0 and 120 min to determine the participant’s glucose tolerance status.
Plasma glucose was measured using an enzymatic calorimetric method (ABX Pentra, Glucose HK CP,
Montpellier, France), while insulin in serum was determined by a chemiluminescent immunometric
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assay (Siemens healthcare Diagnostics, West Sacramento, CA, USA). Fasting insulin levels were not
available from two participants. Insulin resistance measured by homeostatic model of assessment
(HOMA-IR) was computed as (glucose (mmol/l) × insulin (µU/mL))/22.5. Insulin secretion determined
by homeostatic model of assessment (HOMA-B) was calculated using the formula: (insulin (µU/mL) ×
20)/(glucose (mmol/L) − 3.5) [9]. Insulin sensitivity index (ISI0, 120) was calculated using fasting and
2 h glucose and insulin values obtained from the OGTT, as described elsewhere [10].
2.5. Measurement of AGE Levels
Twenty-four hour urine samples were collected and kept cold in thermo bags throughout the
collection period, and then stored at −80 ◦C immediately after return of the samples until analysis.
An ultra-performance liquid chromatography-triple quadruple detector system (Waters, Milford, MA,
USA) was used to determine urinary CML and MG-H1 levels, as described previously [5,11]. Briefly,
an Oasis HLB LP 96-well plate (60 mg; Waters, Hedehusene, Denmark) was used to pre-concentrate
the samples by solid phase extraction (SPE). The SPE cartridges were preconditioned with 1 mL
methanol followed by two washes with the same volume of water. A total of 100 µL urine together
with 10 µL internal standards (30 µg/mL; PolyPeptide Group, Torrance, CA, USA) was loaded
onto the SPE cartridge and eluted with 300 µL 20% methanol/water. The loading and the eluate
were combined, and the solvent was evaporated. The samples were then re-dissolved in 200 µL
26 mmol/L ammonium formate. Liquid chromatography tandem mass spectrometry operated in the
multiple-reaction mode was used to analyze the samples on a 2.1 mm × 15 cm hypercarb column
(3 µm particle size; Thermo Fischer Scientific, Waltham, MA, USA). The gradient used was 0–20%
acetonitrile/26 mmol/L ammonium formate in 0–3 min and 20–60% in 3–10.2 min, and then immediately
back to 100% 26 mmol/L ammonium formate to recalibrate the column for 3.8 min before the next
injection. The flow rate was 0.1 mL/min, and the transitions used for quantification of MG-H1 and
CML were 229 > 166 and 205 > 130, respectively. A Millipore ultra-pure water system was used to
purify the water used for all solutions. Calibration curves were prepared for CML and MG-H1 using
six concentration levels (0, 0.16, 0.31, 0.63, 1.25, and 2.50 µg/mL). The linearity in this concentration
range was 0.9995 for CML, and 0.9998 for MG-H1 levels.
2.6. Statistical Analyses
Normality of distributions was assessed, and skewed parameters were logarithmically transformed
to approximate to normal distribution. Means and standard deviations (SD) were reported unless
otherwise stated. Pearson correlation tests were performed to examine the correlations between levels
of urinary AGEs and cardiometabolic parameters. The associations between urinary AGEs levels
and cardiometabolic parameters were determined using multiple linear regression analyses after
adjustment for age, BMI or WHR, and HOMA-IR. Analyses were performed using SAS Studio 3.4
(SAS Institute Inc, Cary, NC, USA) and p-values were reported to be significant at p < 0.05.
3. Results
3.1. Participant Characteristics
Fifty-eight metabolically healthy women aged 39.98 ± 8.72 years with a BMI of 32.39 ± 4.05 kg/m2
and WHR of 0.92 ± 0.05 were included in the analysis. The average systolic and diastolic blood
pressure was 123.28 ± 13.91 mmHg and 82.26 ± 9.62 mmHg, respectively. Participants had a mean
total cholesterol of 5.04 ± 0.72 mmol/L, LDL of 3.10 ± 0.68 mmol/L, and HDL of 1.37 ± 0.28 mmol/L.
The mean fasting and 2 h glucose levels of the participants were 5.33 ± 0.31 and 5.75 ± 1.09 mmol/L,
respectively (Table 1).
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Table 1. Participant characteristics.
Parameters Mean ± SD
Age, years 39.98 ± 8.72
Weight, kg 90.96 ± 12.40
BMI, kg/m2 32.29 ± 4.05
WHR 0.92 ± 0.05
Systolic blood pressure, mmHg 123.28 ± 13.91
Diastolic blood pressure, mmHg 82.26 ± 9.62
Pulse pressure, mmHg 41.03 ± 7.04
Mean arterial pressure, mmHg 95.92 ± 10.71
Total cholesterol, mmol/L 5.04 ± 0.72
HDL, mmol/L 1.37 ± 0.28
LDL, mmol/L 3.10 ± 0.68
Triglycerides, mmol/L 1.09 ± 0.48
Fasting glucose, mmol/L 5.33 ± 0.31
2 h glucose, mmol/L 5.75 ± 1.09
Fasting insulin, µU/L * 0.91 ± 0.31
2 h insulin, µU/L * 1.73 ± 0.89
HOMA-IR, (µU/L) /(mmol/L) * 0.29 ± 0.29
HOMA-B, % * 1.94 ± 0.26
ISI0, 120 * 1.85 ± 1.31
Urinary CML, µg/mL * 0.26 ± 0.26
Urinary MG-H1, µg/Ml * 0.66 ± 0.28
* Log transformation was performed. n = 56 for fasting insulin, HOMA-IR, HOMA-B, and ISI0, 120. BMI, body mass
index; WHR, waist-to-hip ratio; HOMA-IR, homeostatic model of insulin resistance; HOMA-B, homeostatic model
of insulin secretion; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ISI, insulin sensitivity index;
CML, carboxymethyl lysine; MG-H1, methylglyoxal-hydroimidazolone; SD: standard deviations.
3.2. Correlation Analyses
The results of the correlation analyses between AGE levels and cardiovascular and metabolic
parameters are presented in Table 2.
Table 2. Univariable analyses between advanced glycation end products (AGE) levels and
cardiometabolic parameters.
Parameters
Urinary CML Levels, µg/mL Urinary MG-H1 Levels, µg/mL
r Value p Value r Value p Value
Age, years −0.10 0.27 −0.17 0.20
BMI, kg/m2 0.29 0.02 0.17 0.19
WHR 0.22 0.08 0.14 0.28
Systolic blood pressure, mmHg 0.19 0.13 0.33 0.01
Diastolic blood pressure, mmHg 0.13 0.32 0.26 0.04
Pulse pressure, mmHg 0.19 0.10 0.27 0.04
Mean arterial pressure, mmHg 0.16 0.24 0.34 0.02
Total cholesterol, mmol/L 0.11 0.40 0.26 0.04
HDL, mmol/L −0.05 0.70 0.03 0.81
LDL, mmol/L 0.13 0.32 0.22 0.09
Triglycerides, mmol/L 0.07 0.58 0.12 0.35
Fasting glucose, mmol/L 0.14 0.22 -0.07 0.57
2 h glucose, mmol/L 0.23 0.07 0.02 0.83
Fasting insulin, µU/L 0.37 0.004 0.06 0.62
2 h insulin, µU/L 0.36 0.01 0.14 0.29
HOMA-IR, (µU/L) /(mmol/L) 0.37 0.004 0.05 0.66
HOMA-B, % 0.36 0.01 0.09 0.49
ISI0, 120 −0.22 0.05 −0.08 0.49
All values were log transformed. Pearson correlations were performed. n = 56 for fasting insulin, HOMA-IR,
HOMA-B, and ISI0, 120. BMI, body mass index; WHR, waist-to-hip ratio; HOMA-IR, homeostatic model of insulin
resistance; HOMA-B, homeostatic model of insulin secretion; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; CML, carboxymethyl lysine; MG-H1, methylglyoxal-hydroimidazolone.
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Urinary CML levels were positively correlated with BMI (r = 0.29, p = 0.02), fasting insulin
(r = 0.37, p = 0.004), 2 h insulin (r = 0.36, p = 0.01), HOMA-IR (r = 0.37, p = 0.004), and HOMA-B
(r = 0.36, p = 0.01). There was also a trend for a negative relationship between urinary CML and ISI0, 120
(r = −0.22, p = 0.05). Cardiovascular parameters including blood pressure and lipid levels did not
correlate with urinary CML levels (Table 2).
Urinary MG-H1 levels were correlated with systolic blood pressure (r = 0.33, p = 0.01), diastolic
blood pressure (r = 0.26, p = 0.04), pulse pressure (r = 0.27, p = 0.04), mean arterial blood pressure
(r = 0.3, p = 0.02), and total cholesterol (r = 0.26, p = 0.04), but not with anthropometric and glycemic
parameters (all p > 0.09).
3.3. Multiple Linear Regression Analyses
Results of the regression analyses are presented in Table 3. After adjustment for age and BMI, there
was a trend for positive associations between urinary CML levels and fasting (p = 0.06), 2-h insulin
(p = 0.05) and HOMA-IR (p = 0.06). Urinary MG-H1 levels were positively associated with systolic
(p = 0.01) and diastolic (p = 0.01) blood pressure, pulse pressure (p = 0.02), mean arterial blood pressure
(p = 0.01), total cholesterol (p = 0.01) and LDL cholesterol (p = 0.05) after adjustment for age, BMI and
HOMA-IR. The associations between urinary CML levels and cardiovascular parameters, and between
urinary MG-H1 levels and anthropometric and glycemic measurements remained non-significant after
adjusting for covariates. In addition, urinary CML was not associated with ISI0, 120 after adjusting
for age and BMI. In all multiple linear regression analyses, results were unchanged by replacing BMI
with WHR.
Table 3. Multivariable analyses of urinary AGE levels with cardiometabolic parameters.
Parameters
Urinary CML Levels, µg/mL Urinary MG-H1 Levels, µg/mL
β coefficient (95% CI) p Value β coefficient (95% CI) p Value
Systolic blood pressure, mmHg 0.03 (−0.01, 0.08) 0.11 0.06 (0.02, 0.11) 0.01
Diastolic blood pressure, mmHg 0.02 (−0.02, 0.07) 0.37 0.05 (0.01, 0.17) 0.01
Pulse pressure, mmHg 0.06 (−0.02, 0.14) 0.14 0.08 (0.01, 0.15) 0.02
Mean arterial pressure, mmHg 0.02 (−0.02, 0.07) 0.22 0.06 (0.01, 0.14) 0.01
Total cholesterol, mmol/L 0.04 (−0.02, 0.11) 0.71 0.07 (0.01, 0.13) 0.01
HDL, mmol/L 0.05 (−0.03, 0.14) 0.33 0.02 (−0.06, 0.16) 0.46
LDL, mmol/L 0.03 (−0.07, 0.14) 0.70 0.09 (−0.001, 0.19) 0.05
Triglycerides, mmol/L −0.06 (−0.26, 0.13) 0.36 0.04 (−0.13, 0.23) 0.65
Fasting glucose, mmol/L 0.01 (−0.01, 0.01) 0.16 −0.01 (−0.03, 0.01) 0.54
2 h glucose, mmol/l 0.06 (−0.02, 0.15) 0.71 −0.01 (−0.09, 0.07) 0.85
Fasting insulin, µU/L 0.21 (−0.02, 0.44) 0.06 −0.06 (−0.29, 0.16) 0.58
2 h insulin, µU/L 0.25 (−0.01, 0.51) 0.05 0.04 (−0.21, 0.35) 0.72
HOMA-IR, (µU/L) /(mmol/L) 0.22 (−0.02, 0.47) 0.06 −0.06 (−0.31, 0.17) 0.56
HOMA-B, % 0.16 (−0.04, 0.37) 0.12 −0.04 (−0.24, 0.15) 0.66
ISI0, 120 −0.04 (−0.16, 0.07) 0.41 0.97 (−0.11, 0.10) 0.97
All values were log transformed. Adjusted β coefficients were reported. n = 56 for fasting insulin, HOMA-IR,
HOMA-B, and ISI0, 120. Regression models for cardiovascular parameters were adjusted for age, body mass
index, and HOMA-IR. Regression models for metabolic parameters were adjusted for age and body mass index.
CI, confidence interval; HOMA-IR, homeostatic model of insulin resistance; HOMA-B, homeostatic model of
insulin secretion; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CML, carboxymethyl lysine;
MG-H1, methylglyoxal-hydroimidazolone.
4. Discussion
We investigated the associations between urinary AGE levels and cardiometabolic parameters
in obese, but metabolically healthy Caucasian women. We found that urinary CML levels were
positively associated with obesity and markers of insulin resistance such as fasting and 2 h insulin
levels and HOMA-IR, while urinary MG-H1 levels were associated with cardiovascular parameters
including systolic and diastolic blood pressure, pulse pressure, mean arterial pressure, and total and
LDL cholesterol.
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We report a positive association between urinary CML levels and obesity measured by BMI. Other
studies that involved non-diabetic individuals, however, demonstrated that urinary AGE levels were
not associated with BMI [7,8]. These studies measured small-sized AGE peptides by flow injection
assays, which do not identify any particular AGE. Moreover, a study by Maza and colleagues [7]
involved only adult men, while the other study included elderly subjects aged 70 to 89 years [8], which
could have potentially influenced the association. Obesity is known to increase oxidative stress [12],
and CML levels, which are formed from the oxidative degradation of fructosyl-lysine and by the
reactions of glyoxal and ascorbic acid with lysine residues in proteins [13,14], have been shown to
associate with oxidative stress [13]. Our finding supports the important link between urinary CML
levels and the development of obesity.
We demonstrated that urinary CML levels were associated with markers of insulin resistance
such as fasting and 2 h insulin levels and HOMA-IR, but not with cardiovascular parameters, after
adjustment for age and BMI or WHR. Other studies have also found that urinary CML levels were not
associated with fasting glucose levels [6–8]. A study in elderly people showed no association between
urinary AGEs and insulin levels in both individuals with and without T2DM [8]. The discrepancy
could be the result of a difference in the age of the participants or in the type of AGEs assessed in
urine. We determined specific urinary AGEs (CML and MG-H1 levels) in adult women, while the
other study [8] measured total AGE levels in an elderly population. CML has been shown to activate
inflammatory signaling pathways that contribute to the development of insulin resistance in obese
individuals [15]. Related to this, urinary CML levels have been reported to be elevated in individuals
with T2DM compared with those without T2DM [16,17]. Our data suggest that urinary CML plays a
role in the pathophysiology of insulin resistance in obese individuals even before hyperglycaemia is
evident; however, future studies are required to confirm this.
Methylglyoxal, a highly reactive carbonyl species, is formed by lipid peroxidation, degradation
of glycolic intermediates, and glycated proteins [18]. It has been shown to inhibit antioxidant
enzymes through binding of free sulfhydryl groups at their active sites, and thereby cause oxidative
stress [19]. MG-H1 levels have been suggested to play an important role in the development of
carbonyl stress-induced conditions including hypertension, dyslipidaemia, and atherosclerosis [20,21].
In line with this, we found that urinary MG-H1 levels were associated with systolic and diastolic blood
pressure, pulse pressure, mean arterial blood pressure, and total and LDL cholesterol after adjustment
for age, BMI or WHR, and HOMA-IR, but not with any glycemic measurements. To the best of our
knowledge, no previous studies have reported the relationships between urinary MG-H1 levels and
cardiometabolic parameters. Nonetheless, a study that measured total urinary AGE levels showed
positive associations with systolic and diastolic blood pressure in healthy individuals and patients with
metabolic syndrome [6]. However, methylglyoxal has been positively associated with fasting glucose
levels in patients with T2DM on glucose or lipid lowering treatments [22]. The discrepancy may be
the result of differences in the study populations, as our participants had normal glucose tolerance
and did not use any medications including glucose- or lipid-lowering drugs. Our data suggest that
urinary MG-H1 levels may be important to assess the risk of cardiovascular disease, but this should be
confirmed by future longitudinal studies.
The present study has some limitations. We did not obtain data on dietary AGEs and alcohol intake,
which may have influenced our findings. In addition, circulating AGE levels were not determined,
hence we were unable to show their relationships with urinary AGEs. The study was performed in
non-vegetarian, obese Caucasian women with normal glucose tolerance, thus our results may not be
generalizable to other populations such as men, vegetarians, non-obese individuals, and patients with
hyperglycaemia, as well as other ethnicities. Furthermore, owing to the cross-sectional nature of the
study, we cannot establish causality. Despite these limitations, our participants were metabolically
well-characterized. We were thus able to adjust our findings for potential confounders, such as age,
BMI or WHR, and HOMA-IR.
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In summary, we have demonstrated that urinary CML levels were positively associated with obesity
and markers of insulin resistance, while urinary MG-H1 levels were associated with cardiovascular
parameters including blood pressure and lipid levels in obese, but otherwise healthy women. Our
findings suggest that urinary AGE levels may be useful for assessing future risk of cardiometabolic
syndrome in obese individuals; however, future longitudinal studies including both genders and
individuals without T2DM are highly warranted.
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